Qiagen (NYSE:QGEN) Price Target Raised to $52.00

Qiagen (NYSE:QGEN) had its price target lifted by Robert W. Baird from $50.00 to $52.00 in a report released on Thursday morning, MarketBeat.com reports. Robert W. Baird currently has an outperform rating on the stock.

Other research analysts have also issued research reports about the stock. Barclays set a $40.00 price target on shares of Qiagen and gave the company an “equal weight” rating in a research note on Friday, August 7th. Kepler Capital Markets set a $38.60 price objective on shares of Qiagen and gave the stock a “hold” rating in a research report on Thursday, June 25th. Morgan Stanley restated an “overweight” rating on shares of Qiagen in a report on Friday, September 11th. Stifel Nicolaus set a $40.00 target price on Qiagen in a research report on Friday, August 7th. Finally, JPMorgan Chase & Co. increased their target price on Qiagen from $50.00 to $55.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 14th. Four research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the stock. According to MarketBeat.com, Qiagen has an average rating of “Hold” and an average price target of $44.43.

Qiagen Trading Up 0.4%

Shares of NYSE:QGEN opened at $50.42 on Thursday. Qiagen has a 52-week low of $32.53 and a 52-week high of $57.81. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.31 and a current ratio of 2.85. The company has a market capitalization of $10.39 billion, a P/E ratio of 25.83, a price-to-earnings-growth ratio of 5.01 and a beta of 0.61. The company has a 50-day simple moving average of $44.44 and a 200 day simple moving average of $40.64.

Qiagen (NYSE:QGEN) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share for the quarter, topping analysts’ consensus estimates of $0.60 by $0.02. The firm had revenue of $535.04 million for the quarter, compared to the consensus estimate of $527.50 million. Qiagen had a return on equity of 14.47% and a net margin of 19.49%. The business’s revenue was up .2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.60 earnings per share. Qiagen has set its FY 2026 guidance at 2.430- EPS. Sell-side analysts forecast that Qiagen will post 2.44 earnings per share for the current year.

Hedge Funds Weigh In On Qiagen

Several institutional investors and hedge funds have recently modified their holdings of QGEN. Assenagon Asset Management S.A. increased its position in Qiagen by 1.9% during the third quarter. Assenagon Asset Management S.A. now owns 15,722 shares of the company’s stock worth $691,000 after acquiring an additional 286 shares during the period. Allworth Financial LP boosted its holdings in Qiagen by 20.8% in the 2nd quarter. Allworth Financial LP now owns 1,841 shares of the company’s stock valued at $72,000 after purchasing an additional 317 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in Qiagen by 46.8% in the 1st quarter. EverSource Wealth Advisors LLC now owns 2,746 shares of the company’s stock valued at $110,000 after purchasing an additional 876 shares during the period. Quadrant Capital Group LLC boosted its holdings in Qiagen by 2.4% in the 3rd quarter. Quadrant Capital Group LLC now owns 42,660 shares of the company’s stock valued at $1,938,000 after purchasing an additional 1,003 shares during the period. Finally, Hilltop National Bank acquired a new position in shares of Qiagen during the 2nd quarter worth approximately $50,000. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Qiagen

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: Qiagen updated third-quarter 2026 guidance to adjusted EPS of $0.65 and revenue of $548 million, above consensus estimates of $0.62 and $534.1 million, respectively. The figures are consistent with the company’s preliminary results and signal better-than-expected operating performance.
• Positive Sentiment: EQT agreed to acquire Qiagen in an all-cash transaction valued at approximately $12.1 billion, offering €46.50 per share. The takeover provides a defined valuation and has been unanimously accepted, with the transaction nearing completion. Qiagen to Be Acquired by EQT for $12.1 Billion in All-Cash Deal
• Positive Sentiment: Robert W. Baird raised its price target to $52 from $50 and upgraded the stock to “outperform,” citing potential value near the takeover consideration. Robert W. Baird Qiagen rating
• Neutral Sentiment: Unusually heavy call-option activity suggests increased short-term trading interest, with call purchases roughly doubling typical volume, but it does not establish a fundamental change in valuation.
• Neutral Sentiment: JPMorgan reaffirmed its “neutral” rating while lowering its price target to $52 from $55, leaving limited projected upside relative to the current trading level. JPMorgan Qiagen rating
• Negative Sentiment: Law firms Brodsky & Smith and Halper Sadeh announced investigations into whether Qiagen obtained a fair price for shareholders. Such reviews could create deal uncertainty, although they do not currently indicate that the transaction will be blocked. Brodsky & Smith shareholder investigation

Qiagen Company Profile

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.

Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables.